Oxford Biomedica Loss Widens, Sees Progress in 2017
March 16 2017 - 3:58AM
Dow Jones News
By Philip Waller
LONDON--Gene and cell therapy group Oxford Biomedica PLC
(OXB.LN) Thursday posted a wider 2016 loss, though it forecasted
progress with core technology and new partnerships in 2017.
Oxford said its loss in the year to Dec. 31 rose to 20.3 million
pounds ($24.9 million) from GBP16.9 million a year earlier despite
higher revenue of GBP27.8 million, up from GBP15.9 million.
The company attributed the wider loss to higher depreciation,
amortization and share-option charges as well as interest charges
inflated by the weakness of sterling against the dollar.
The company said its oss before interest, taxes, depreciation
and amortization fell to GBP7.1 million from GBP12.1 million.
Oxford said its work with Switzerland's Novartis was progressing
well, with potential blockbuster cancer treatment CTL019 close to
market.
Chief Executive John Dawson said: "Beyond Novartis, we have
added new revenue-generating partnerships and collaborations during
2016 which are progressing well and are confident we can add
further relationships during 2017."
-Write to Philip Waller at philip.waller@wsj.com
(END) Dow Jones Newswires
March 16, 2017 03:43 ET (07:43 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Sep 2023 to Sep 2024